MAPT and Alzheimer disease: Broadly speaking, it has been reproducibly shown that AD patients that are carriers of APOE2 have significantly reduced cortical Aβ deposition [11], while the effect of APOE2 on tau pathology has not been as conclusive [10, 79, 80].